Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04874714
Status:
TERMINATED
Last Update Posted:
2023-12-19
First Post:
2021-03-26
Brief Title:
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic RhinitisRhinoconjunctivitis
Sponsor:
Inmunotek SL
Organization:
Inmunotek SL
Study Overview
Official Title:
Prospective Randomized Placebo-controlled Multi-center Trial Comparing the Efficacy and Safety of Subcutaneous Immunotherapy With a Mixture of Grasses and Mites at Adequate Doses Versus Monotherapy for the Treatment of Allergy
Status:
TERMINATED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to the low recruitment rate since the start of the trial
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prospective randomized placebo-controlled multicenter of 3 active treatment groups compared to 1 placebo group for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and allergic rhinitisrhinoconjunctivitis intermittent or persistent due to hypersensitivity to house dust mites Dermatophagoides pteronyssinus and or D farinae and grass pollen
Detailed Description:
Double blind parallel placebo-controlled study The subjects will receive medication during 11 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-003715-22 | EUDRACT_NUMBER | None | None |